Quantcast
Last updated on April 18, 2014 at 7:15 EDT

Latest Eisai Co. Ltd. Stories

2009-06-09 08:00:00

Antibody Targets Endosialin, a Protein Widely Expressed on Tumors and Tumor Blood Vessel Cells EXTON, Pa., June 9 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application to study MORAb-004 in the treatment of patients with solid tumors. MORAb-004 targets endosialin, a protein expressed on cells associated with tumors and tumor blood vessel cells....

2009-05-19 07:00:00

Agreement Underscores Morphotek's Commitment to the Development of Farletuzumab for Ovarian Cancer Agreement Highlights Lonza's Ability to Offer Specialty Development and Manufacturing Solutions EXTON, Pa. and BASEL, Switzerland, May 19 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, and Lonza Group Ltd jointly announced today that they have executed a manufacturing services agreement to support the development and manufacturing of a subset of...

2009-05-04 08:00:00

Research presented to the 2009 Congressional Black Caucus Spring Health Braintrust finds African American and Hispanic adults are misinformed about Alzheimer's but support a screening test WOODCLIFF LAKE, N.J., May 4 /PRNewswire/ -- African American and Hispanic adults are more concerned about Alzheimer's disease, but are less informed about prevention of and risk factors than Caucasians, according to new survey results announced today by Eisai, Inc. Dr. Sharon Richardson, vice president of...

2009-03-25 06:16:00

ROCKVILLE, Md. and EXTON, Pa., March 25 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) and Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies in the fields of oncology and immunology that specifically target antigens discovered by HGS. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) "The rapid...

2009-03-23 07:00:00

EXTON, Pa., March 23 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that the U.S. Food and Drug Administration (FDA) has agreed to and approved the design of a single, pivotal, Phase III clinical trial evaluating farletuzumab (also known as MORAb-003) in platinum-sensitive ovarian cancer patients experiencing their first relapse. The agreement was made under the Special Protocol Assessment (SPA) procedure. "We are pleased that the FDA...

2009-03-09 12:43:00

SAN JOSE, Calif., March 9 /PRNewswire/ -- Teikoku Pharma USA Inc., the international specialty pharmaceutical company, announces that it has signed an exclusive worldwide (excluding Japan) licensing agreement with Eisai Co., Ltd. to develop and commercialize a new transdermal formulation of donepezil, a leading compound for the treatment of Alzheimer's disease in the world. The transdermal formulation is a once-a-week patch that continuously delivers donepezil through the skin into the...

2009-03-02 08:00:00

EXTON, Pa., March 2 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that it has commenced a multi-centered Phase II study of its MORAb-009 monoclonal antibody in mesothelioma. The study will evaluate MORAb-009, plus the chemotherapy drugs pemetrexed and cisplatinum, as a first-line treatment for patients with mesothelioma. The primary objective of the study is to assess the efficacy of MORAb-009 as combination therapy with the...

2009-02-19 09:02:00

LONDON, February 19 /PRNewswire-FirstCall/ -- - Eisai Set to Become an Emerging Leader in the Treatment of Epilepsy Eisai Europe Ltd (London; Chairman & CEO Yutaka Tsuchiya), the European subsidiary of Eisai Co., Ltd. (Tokyo, President & CEO: Haruo Naito), and Bial-Portela & CA, S.A., (S. Mamede do Coronado, Portugal, CEO Dr Luis Portela) today announced the signing of a licence and co-promotion agreement in which Eisai receives a sole license to market, promote and...

2008-12-14 19:00:00

WOODCLIFF LAKE, N.J., Dec. 14 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has approved LUSEDRA(TM) (fospropofol disodium) Injection, an intravenous sedative-hypnotic agent for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures. In the approval, the FDA required that LUSEDRA be used only by persons trained in the administration of general anesthesia and that...

2008-12-08 17:30:00

Response Observed Across All Subtypes of AML, Including Those with Poorest Prognoses SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Eisai Corporation of North America today announced data from a Phase II trial evaluating a five-day dosing regimen of Dacogen(R) (decitabine for injection) in acute myeloid leukemia (AML), the most common form of leukemia. The study involved elderly patients with AML, who often have limited options due to comorbidities and are typically considered ineligible for...